BioCryst Pharmaceuticals BCRX Equity modification associated with sale of BioCryst Ireland

Equity modification associated with sale of BioCryst Ireland at other companies

AlkermesALKS

$26.36M-18.1%

Sempra EnergySRE

$442.75M—

Krystal Biotech, Inc.KRYS

$193.49M+30.3%

PNC Financial ServicesPNC

$10.51B+11.3%

Liberty EnergyLBRT

$0+100%

Voya FinancialVOYA

$14.25M—

Other financials

Income statement

See full

Revenue$156.4M+7.5%

Gross profit$151.0M+7.1%

Operating income-$701.6M-3,405%

Net income-$721.8M-2,255,763%

EPS (diluted)-$2.98—

Balance sheet

See full

Cash & equivalents$173.4M+62.2%

Total debt$411.8M+24.7%

Total equity-$553.8M-22.6%

Total assets$465.1M-3.1%

Cash flow

See full

Operating cash flow-$61.8M-125%

CapEx$403.0K+182%

Free cash flow-$62.2M-125%

Valuation

See full

Market cap$2.37B+52.3%

Enterprise value$2.6B+46.7%

P/S2.7×-0.4×

Profitability

See full

Gross margin97.8%+0.8pp

Operating margin-43.1%-49.7pp

Net margin-51.7%-69.7pp

FCF margin35%—

Returns & leverage

See full

Return on equity-882.8%—

Debt / equity0.1×—

Current ratio1.9×-1.0×

Where this comes from

Reported directly by BioCryst Pharmaceuticals in its filing.

Tagged under the XBRL concept bcrx:EquityModificationAssociatedWithSaleOfBusiness.

The official record: BioCryst Pharmaceuticals’s 10-K, filed February 26, 2026, on SEC EDGAR. View the filing →

Ask your AI about BioCryst Pharmaceuticals's equity modification associated with sale of biocryst ireland.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is BioCryst Pharmaceuticals's equity modification associated with sale of biocryst ireland?: BioCryst Pharmaceuticals (BCRX) reported equity modification associated with sale of biocryst ireland of $4.39M in Q4 2025.
What does equity modification associated with sale of biocryst ireland mean?: The financial impact resulting from adjustments to equity-based compensation or ownership structures triggered by the divestiture of a business unit. This captures non-recurring costs or gains associated with corporate restructuring and asset sales.